Table 1

Patient baseline characteristics

CharacteristicValue
Number of patients analyzed 590 
Median age, y (range) 42 (18-68) 
Disease  
    CML 154 (26) 
    AML 144 (24) 
    MDS 103 (17) 
        RA/RARS/RCMD 35 (6) 
        RAEB 26 (4) 
        AML from MDS 42 (7) 
    ALL 74 (13) 
    NHL 68 (12) 
    MPD 17 (3) 
    CLL 14 (2) 
    HD 6 (1) 
    Multiple myeloma 4 (1) 
    CMML 4 (1) 
    LGL leukemia 1 (0) 
    NK leukemia 1 (0) 
Stage  
    Untreated 74 (13) 
    CR1 222 (38) 
    Second or later CR 66 (11) 
    PR 61 (10) 
    Induction failure 85 (14) 
    Relapse 82 (14) 
Graft source  
    Bone marrow 317 (54) 
    Peripheral blood 269 (46) 
    Cord blood 4 (1) 
Match  
    MRD 270 (46) 
    MUD 242 (41) 
    Mismatched 78 (13) 
Conditioning  
    Cy/TBI 567 (96) 
    Bu/Cy 22 (4) 
    Other 1 (0) 
GVHD prophylaxis  
    CnI + Mtx ± steroids 281 (48) 
    CnI + Siro ± Mtx 198 (34) 
    TCD 68 (12) 
    Other 43 (7) 
Male recipient/female donor 122 (21) 
CMV seropositivity  
    Recipient 244 (41) 
    Donor 221 (37) 
CharacteristicValue
Number of patients analyzed 590 
Median age, y (range) 42 (18-68) 
Disease  
    CML 154 (26) 
    AML 144 (24) 
    MDS 103 (17) 
        RA/RARS/RCMD 35 (6) 
        RAEB 26 (4) 
        AML from MDS 42 (7) 
    ALL 74 (13) 
    NHL 68 (12) 
    MPD 17 (3) 
    CLL 14 (2) 
    HD 6 (1) 
    Multiple myeloma 4 (1) 
    CMML 4 (1) 
    LGL leukemia 1 (0) 
    NK leukemia 1 (0) 
Stage  
    Untreated 74 (13) 
    CR1 222 (38) 
    Second or later CR 66 (11) 
    PR 61 (10) 
    Induction failure 85 (14) 
    Relapse 82 (14) 
Graft source  
    Bone marrow 317 (54) 
    Peripheral blood 269 (46) 
    Cord blood 4 (1) 
Match  
    MRD 270 (46) 
    MUD 242 (41) 
    Mismatched 78 (13) 
Conditioning  
    Cy/TBI 567 (96) 
    Bu/Cy 22 (4) 
    Other 1 (0) 
GVHD prophylaxis  
    CnI + Mtx ± steroids 281 (48) 
    CnI + Siro ± Mtx 198 (34) 
    TCD 68 (12) 
    Other 43 (7) 
Male recipient/female donor 122 (21) 
CMV seropositivity  
    Recipient 244 (41) 
    Donor 221 (37) 

Values indicate number of patients (%) unless otherwise indicated. Percentages may not add to 100 because of rounding.

CML indicates chronic myelogenous leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess blasts; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MPD, myeloproliferative disease excluding CML and CMML; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; CMML, chronic myelomonocytic leukemia; LGL, large granular lymphocyte; NK, natural killer cell; CR, complete remission; PR, partial remission; MRD, matched related donor; MUD, matched unrelated donor; Cy, cyclophosphamide; TBI, total body irradiation; Bu, busulfan; GVHD, graft-versus-host disease; CnI, calcineurin inhibitor (cyclosporine or tacrolimus); Mtx, methotrexate; ±, with or without; Siro, sirolimus; TCD, T-cell depletion; and CMV, cytomegalovirus.

Close Modal

or Create an Account

Close Modal
Close Modal